Lemtrada Fears May Be Overdone

Regulators may have scared potential Lemtrada patients away when highlighting the risks of stroke and heart attack patients could suffer

Thursday, January 30, 2020 - Relapse-remitting multiple sclerosis (RRMS) patients today must understand the risks of the drug and balance them against the many benefits the drug can offer. RRMS patient report having intermittent attacks followed by periods of remission. Lemtrada patients sometimes rave about the long-term benefits the drug has afforded them for preventing or delaying the progression of their disease. Multiple Sclerosis News Today (MSNT) reported the results of a study called "Alemtuzumab CARE-MS I 5-year follow-up" of Lemtrada patients over five years and found that the drug is highly effective. The study also pointed out that few people developed new brain lesions that required a double dose of the treatments. MSNT reports that 96% of the 367 patients in the study remained relapse-free for the full five years. Over 80% of the study's participants "were free from six-month confirmed disability worsening, and about one-third had six-month confirmed disability improvement." Most patients showed no signs of the disease after about 3 years. Adverse side effects from Lemtrada treatments were limited to headaches, fever, and rashes. Lemtrada stroke lawsuits are represented by top national attorneys with vast experience litigating pharmaceutical lawsuits and offer a no obligation free consultation.

Lemtrada is considered a drug of last resort in the treatment of relapse-remitting multiple sclerosis (RRMS). The disease first occurs in young men and women in their late 20's and early 30's beginning with numbness in the legs or arms. The disease progresses to active periods called flare-ups where a patient experiences the loss of control of the limbs and eventually the inability to get out of bed. The disease goes into remission periods that can last months or more. In addition to numbness and tingling in the extremities, blurry vision and jumpy eyes can be early warning signs that you may have the disease. Lemtrada can only be given to patients after two or more alternative drugs have failed. The drug carries the risk of causing an immediate stroke within 24-hours of receiving a treatment which consists of six sessions over two weeks. It is only recently that the maker of Lemtrada, Sanofi, acknowledged and warned patients of these potentially life-threatening risks. Patients that have been injured by the drug have consulted with Lemtrada stroke attorneys to see if they qualify to file a claim against the drug's maker. Lemtrada patients have reported serious, life-threatening side effects including irreversible paralysis from having a stroke and immediate death from a heart attack. Lemtrada causes tears in the arterial lining of the head and neck leading to stroke and brain bleeding. Lemtrada strokes can also result in permanent brain damage.

Lemtrada, (alemtuzumab) is a monoclonal antibody that works by attaching to the CD52 protein in white blood cells, the building blocks of the human immune system, and kills them, causing them to be replaced with new healthy cells. Lemtrada treatments are infusion IV drips performed annually in a two-day session. Lemtrada mitigates the intensity of the RRMS lapses and extends the remission. Lemtrada patients pay a price for the drug's effectiveness as it is considered one of the most dangerous on the market. Doctors that administer the drug must do so in a hospital with an emergency room available.

More Recent Lemtrada Stroke Lawsuit News:

• Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
• The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
• RRMS Has Different Stages With Different Symptoms | 4/5/2021
• Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
• Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
• Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
• MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
• Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
• Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
• Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
• People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
• Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
• Lemtrada Patients Have May Have Safer Options | 12/8/2020
• Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
• Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
• Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
• Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
• Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
• Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
• Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
• Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
• Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
• Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
• Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
• RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
• New Information About COVID19 and Taking Lemtrada | 7/16/2020
• The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
• Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
• A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos | 6/22/2020
• Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
• Canadians Have One of the World's Highest Rates of Multiple Sclerosis | 5/28/2020
• RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
• Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
• Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
• Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
• Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic | 4/10/2020
• Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
• Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
• Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
• Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
• Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
• Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
• Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug | 2/4/2020
• Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
• One Last Lemtrada Warning for 2019 | 1/2/2020
• RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
• Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
• Lemtrada Side Effect Awareness Requirements | 12/11/2019
• Lemtrada is serious medication for a serious condition | 11/21/2019
• More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
• RRMS Patients May Look To Alternatives To Lemtrada | 11/6/2019
• Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
• Understand The Pros and Cons of Lemtrada RRMS Treatments | 10/16/2019
• Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
• Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
• RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
• Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
• Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
• Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
• Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
• Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
• Lemtrada Patients Report Promising Results | 8/1/2019
• The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
• What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
• Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
• Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
• Treating Multiple Sclerosis From Many Angles | 6/21/2019
• Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
• A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects | 6/11/2019
• A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
• Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
• The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
• Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke | 5/10/2019
• The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
• The Pros and Cons of Lemtrada Therapy | 4/19/2019
• Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
• Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects. | 4/9/2019
• MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
• Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
• Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
• Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.